Dr. Chris Hourigan is board-certified hematologist-oncologist dedicated to the detection, prevention and treatment of acute myeloid leukemia (AML) relapse. He runs a research laboratory at the National Heart, Lung and Blood Institute of the National Institutes of Health in Bethesda Maryland focusing on the detection of AML measurable residual disease (MRD) using novel genomic and molecular methods.
Dr. Hourigan attended medical school and received his PhD from the University of Oxford before completing residency and clinical and research fellowship training at Johns Hopkins School of Medicine. In addition to his work in the laboratory at NIH he is also a part-time Associate Professor of Oncology at Johns Hopkins.
Dr. Hourigan is the recipient of many awards including the Presidential Early Career Awards for Scientists and Engineers (PECASE) in 2019, election to honorary fellowship of the Royal College of Physicians (London), the 2018 Early Career Physician Award from the Virginia Chapter of the American College of Physicians, the 2017 National Heart, Lung and Blood Institute Directors Award, Fellowship of the American College of Physicians (2013), election to the Johns Hopkins Medical School Chapter of Alpha Omega Alpha (2009), the Patrick Murphy Award for Resident Teacher from Johns Hopkins Bayview Medical Center (2009) and the Sidney Truelove Prize from Oxford University Medical School (2006).
He is married, with two sons.